Acomplia could reach sales of $3 billion per year

Share this article:

Sanofi-Aventis' new obesity drug Acomplia could eventually generate sales of over $3 billion a year, its chairman told Reuters news service yesterday.
"I can tell you that for such a product, in my expectations, three (billion dollars) is not too much," Jean-Francois Dehecq said during a meeting of pharmaceutical executives in Brussels, commenting on forecasts for the medicine.
Sanofi-Aventis anticipates the launch of Acomplia, which also helps people quit smoking, to take place in the first part of 2006.
The drug is among the world's most anticipated since a global obesity epidemic threatens the health of millions of people in developed countries.

 

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.